Updated clinical trial simulation software saves time and money

3 Jun 2019

One customer saves $25m and 3 years' development time in their clinical development strategy.

Data analysis and clinical trial software specialist, Exploristics, plans to launch an updated version of its cloud-based data analytics platform for clinical trial design, KerusCloud 2.0, by the end of the summer.

Updated clinical trial simulation software saves time and money

The groundbreaking software offers unique second-generation simulation capabilities providing a virtual environment for optimising clinical study design and data analysis through the processing power of cloud computing.

First launched in 2018, KerusCloud is currently the only software available that can simulate trials with multiple correlated outcomes, allowing it to untangle the complex relationships between the many biological factors that can influence a study’s outcome. Its cloud-based approach makes the simulation of complex studies an affordable and accessible option regardless of project size.

KerusCloud 2.0 builds on its unique capability enabling more realistic clinical trial simulations thanks to a new feature that generates correlated data for sub-groups within a patient population, facilitating the investigation of precision medicine or adaptive development pathways.

This means that clusters of patients in a clinical trial grouped by factors such as genetics, risk factors and biological sub-types can be looked at in greater detail, enabling clinical development teams to pursue more complex clinical strategies with in-silico design tools.

The latest version also delivers an enhanced user experience with simulations that are 96 times faster allowing users to explore a greater range of options in a much shorter time period. In addition, increased security features have been added, such as multi-factor authentication.

KerusCloud 2.0 also provides improved, interactive graphical representations that allow users to explore multiple design scenarios for their trial to make informed data-driven decisions aligned to their clinical and business objectives.

Dr Aiden Flynn, CEO of Exploristics, who founded the business in 2009, said: “We’ve already witnessed the profound difference KerusCloud can make to our customers’ clinical trials, with one customer saving $25m and 3 years' development time in their clinical development strategy.”

“The updated KerusCloud 2.0 puts clinical development teams at the forefront of complex study design supporting key-decision-making to optimise and accelerate clinical development strategies.”

To support KerusCloud 2.0, Exploristics will be offering enhanced consulting services with a dedicated team of experts available to ensure that customers can reap the full benefit of the new version as they confront the challenges of increasingly complex clinical scenarios.

Dr Flynn continued: “We work continuously to ensure our software can meet the evolving needs of clinical development teams and provide them with the necessary support to implement its unique capabilities for optimising, data-driven clinical trial design.

“Removing barriers to state-of-the-art clinical trial planning is vital to transforming global clinical practice and improving the quality of clinical research and we believe KerusCloud 2.0 will play a key role in that.”

The potential of the KerusCloud platform to transform the speed and efficiency of bringing new medicines to market has been recognised by government bodies and Exploristics was recently awarded a £1m Innovate UK loan to extend its capabilities by integrating it into an intelligent software ecosystem.

The KerusCloud Ecosystem will be revolutionary, enabling access to diverse clinical data sources to create an unparalleled knowledge base for selected therapeutic areas and development programs. Evolving with use, the ecosystem will inform and generate the most accurate study simulations available to date, supporting the complex trial planning now needed in the development of new therapeutic interventions.

Read More

Related news

Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Cyclolab Ltd strengthens its position in the market

Cyclolab Ltd strengthens its position in the market

1 Jul 2019

Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Clinical supply milestone reached for triple-negative breast cancer treatment

Clinical supply milestone reached for triple-negative breast cancer treatment

12 Jun 2019

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.

Read more 
Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

11 Jun 2019

No meaningful difference between the two study groups regardless of age, sex, race or ethnicity.

Read more 
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

6 Jun 2019

Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.

Read more 
Lilly gets its hands on non-opioid pain asset

Lilly gets its hands on non-opioid pain asset

4 Jun 2019

Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.

Read more 
Merck bolsters oncology pipeline with acquisition

Merck bolsters oncology pipeline with acquisition

22 May 2019

Acquisition includes novel late-stage renal cell carcinoma candidate, PT2977.

Read more 
Follicum files patent application for new topical formulation for hair loss

Follicum files patent application for new topical formulation for hair loss

30 Apr 2019

Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.

Read more